Relation Therapeutics Ltd bags US$35m in seed financing.

London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.

Researcher find potential target for atherosclerosis

TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.

Obesity: Arecor Therapeutics partners with TRx Biosciences

British companies Arecor Therapeutics plc and TRx Biosciences Ltd combine their technologies to formulate an oral GLP-1 receptor agonist with enhanced bioavailability<br />&nbsp;&nbsp;&nbsp;

Scientist create non-digestible aptamer

German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.

Scientists create non-digestible aptamer

German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.

SynaptixBio Ltd gets FDA ODD for leukodystrophy

Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.

Bayer SE secures rights to in €310m deal

Bayer AG has purchased European commercialisation rights for the transthyretin amyloid cardiomyopathy candidate acoramidis from BridgeBio Inc.<i> </i>

PulseSight to disrupt AMD space

<span style="mso-ansi-language:EN-GB" lang="EN-GB">PulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive </span><span style="mso-bidi-font-family:Aptos;mso-bidi-theme-font:minor-latin;color:#272727; mso-ansi-language:EN-US" lang="EN-US">delivery platform </span><span […]

Swiss vaccine developer Limma Tech get CARB-X grant

Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the&nbsp;Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).